^
Association details:
| Biomarker: | CD19 deletion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Prediction of Patients at Risk of CD19Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia
Published date:
11/06/2019
Excerpt:
Since CD19Neg relapses also occur in patients treated with other CD19-directed immunotherapies, like blinatumomab...Moreover, after CD19 loss, there are also increases in levels of phosphorylated proteins pSYK, pSRC and pSTAT5, involved in IL7 receptor and pre-BCR signaling pathways, essential for B cell development....exploration and validation of these therapeutic targets could significantly improve clinical outcome and care of patients with CD19Neg B-ALL
DOI:
https://doi.org/10.1182/blood-2019-128883
